TELMISARTAN-HCTZ TABLET

Quốc gia: Canada

Ngôn ngữ: Tiếng Anh

Nguồn: Health Canada

Thành phần hoạt chất:

TELMISARTAN; HYDROCHLOROTHIAZIDE

Sẵn có từ:

PRO DOC LIMITEE

Mã ATC:

C09DA07

INN (Tên quốc tế):

TELMISARTAN AND DIURETICS

Liều dùng:

80MG; 12.5MG

Dạng dược phẩm:

TABLET

Thành phần:

TELMISARTAN 80MG; HYDROCHLOROTHIAZIDE 12.5MG

Tuyến hành chính:

ORAL

Các đơn vị trong gói:

30/100

Loại thuốc theo toa:

Prescription

Khu trị liệu:

ANGIOTENSIN II RECEPTOR ANTAGONISTS

Tóm tắt sản phẩm:

Active ingredient group (AIG) number: 0244783001; AHFS:

Tình trạng ủy quyền:

MARKETED

Ngày ủy quyền:

2012-11-22

Đặc tính sản phẩm

_ Telmisartan-HCTZ _
_Page 1 of 61_
PRODUCT MONOGRAPH
INCLUDING PATIENT MEDICATION INFORMATION
PR
TELMISARTAN-HCTZ
Telmisartan/Hydrochlorothiazide Tablets
Tablet, 80 mg / 12.5 mg and 80 mg / 25 mg, Oral
USP
Angiotensin II AT
1
Receptor Blocker/Diuretic
PRO DOC LTÉE.
2925, boul. Industriel
Laval, Quebec
H7L 3W9
Submission Control Number: 270403
Date of Initial Authorization:
NOV 01, 2012
Date of Revision:
JAN 9, 2023
_ Telmisartan-HCTZ _
_Page 2 of 61_
RECENT MAJOR LABEL CHANGES
7 WARNINGS AND PRECAUTIONS, Ophthalmologic
05/2022
4 DOSAGE AND ADMINISTRATION
01/2023
7 WARNINGS AND PRECAUTIONS
01/2023
TABLE OF CONTENTS
SECTIONS OR SUBSECTIONS THAT ARE NOT APPLICABLE AT THE TIME OF
AUTHORIZATION ARE NOT LISTED.
RECENT MAJOR LABEL CHANGES
.............................................................................................
2
TABLE OF CONTENTS
...............................................................................................................
2
PART I: HEALTH PROFESSIONAL INFORMATION
.......................................................................
4
1
INDICATIONS
....................................................................................................................
4
1.1 Pediatrics
.....................................................................................................................
4
1.2 Geriatrics
.....................................................................................................................
4
2 CONTRAINDICATIONS
......................................................................................................
4
3
SERIOUS WARNINGS AND PRECAUTIONS BOX
................................................................. 5
4
DOSAGE AND ADMINISTRATION
......................................................................................
5
4.1 Dosing Considerations
.................................................................................................
5
4.2 Recommended Dose and Dosage Adjustment
.........................................